Pan-Cancer Analysis Maps PTPN3’s Contrasting Roles Across Tumors

A pan-cancer study has mapped the behavior of the protein tyrosine phosphatase non-receptor type 3, known as PTPN3, across human malignancies, and the picture that emerges is one of striking heterogeneity rather than a single uniform role.

The research, published open access in Discover Oncology on 29 October 2026 by Jigu A, Yanyan Chen and Muzhapaer Abudukeremu, set out to characterize how PTPN3’s molecular and clinical associations vary among cancers, motivated by the protein’s known involvement in tumor-cell signaling and lymphocyte activation.

Methodologically, the team drew on several large public platforms. Gene expression, pathological stage and survival data came from TCGA, GTEx, TIMER2.0 and GEPIA2. Protein-level information, including total abundance and site-specific phosphorylation, was examined using CPTAC and UALCAN data. Genomic alterations and their survival associations were characterized through cBioPortal, while TIMER2.0 was used to estimate the abundance of cancer-associated fibroblasts in the tumor microenvironment.

The results show that PTPN3 transcript and protein expression differ substantially across cancer types. Survival associations run in opposite directions depending on the malignancy: higher PTPN3 expression was linked to poorer overall survival in adrenocortical carcinoma, breast invasive carcinoma and uterine carcinosarcoma, but to more favorable overall survival in kidney renal clear cell carcinoma and uterine corpus endometrial carcinoma.

Disease-free survival followed a similar split pattern. Higher expression was associated with poorer disease-free survival in adrenocortical carcinoma, lung squamous cell carcinoma and uterine carcinosarcoma, whereas kidney renal clear cell carcinoma again showed a more favorable outcome at higher expression levels.

Genomic analysis added further texture. Uterine corpus endometrial carcinoma exhibited the highest frequency of PTPN3 alterations, and the specific A716T variant was observed in lung squamous cell carcinoma, uterine corpus endometrial carcinoma and colon adenocarcinoma. Meanwhile, nine phosphorylation sites displayed differences that were specific to particular cancer types and particular sites across six CPTAC cohorts, suggesting that regulation of the protein at the post-translational level varies widely between tumors.

The study also probed the tumor microenvironment. PTPN3 expression showed positive or negative correlations with estimated cancer-associated fibroblast abundance, with the direction of the relationship depending on both the cancer type and the computational algorithm used, a caveat the authors note explicitly.

At the molecular network level, PTPN3 expression was positively correlated with EGLN1, RORC, CMYA5, ASB16 and PHKA1, and functional enrichment analysis highlighted PI3K–Akt signaling and cytoskeleton-related functions as prominent themes among its associations.

The authors are careful about the limits of their work. These are database-derived associations that generate testable hypotheses, they conclude, but they do not establish PTPN3 as an independent prognostic or therapeutic biomarker. The pan-cancer map they provide is a starting point for targeted experimental follow-up rather than a clinical verdict.

Subject of Research: Pan-cancer characterization of the PTPN3 gene across human malignancies

Article Title: Comprehensive pan-cancer characterization of PTPN3 reveals its prognostic, immunological, and tumorigenic significance across human malignancies

Article References: A, J., Chen, Y., & Abudukeremu, M. (2026). Comprehensive pan-cancer characterization of PTPN3 reveals its prognostic, immunological, and tumorigenic significance across human malignancies. Discover Oncology. https://doi.org/10.1007/s12672-026-06181-9

Image Credits: AI Generated

DOI: 10.1007/s12672-026-06181-9

Keywords: PTPN3, pan-cancer, TCGA, CPTAC, prognosis, phosphorylation, cancer-associated fibroblasts, PI3K-Akt signaling, genomic alterations, bioinformatics, Discover Oncology, Comprehensive